Granulokine

Granulokine is a prescription medication containing the active ingredient filgrastim, supplied in an injectable form for intravenous or subcutaneous administration. It is classified as a granulocyte colony‑stimulating factor (G‑CSF) and is marketed in the European Union. The product is used to stimulate neutrophil production in patients with certain hematologic conditions. It is available only by prescription and is not an over‑the‑counter product in most EU countries.

Granulokine is indicated for several clinical situations in which neutrophil counts are low or need to be increased.

- Chemotherapy‑induced neutropenia to reduce the risk of infection. - Aplastic anemia to support bone‑marrow recovery. - Mobilization of peripheral blood progenitor cells for stem‑cell collection. - Preparation for bone‑marrow transplantation to improve engraftment. - Treatment of severe chronic neutropenia when other therapies are insufficient.

The safety profile of Granulokine includes both frequently observed reactions and less common but potentially serious events.

Common: - Bone pain, especially in the hips, sternum or long bones. - Mild fever or chills. - Headache or dizziness. - Injection‑site erythema or swelling.

Serious: - Splenic rupture or enlargement. - Acute respiratory distress syndrome. - Severe allergic reactions such as anaphylaxis.

The clinician should evaluate several precautionary factors before initiating Granulokine therapy to minimize risk.

- Assess baseline neutrophil count and overall bone‑marrow function. - Use caution in patients with a history of splenic disorders or abdominal trauma. - Monitor for signs of hypersensitivity during and after administration. - Adjust dosing in patients with renal impairment as recommended by prescribing information. - Avoid use in individuals with known hypersensitivity to filgrastim or any excipients. - Consider pregnancy and lactation status; data are limited, so weigh potential benefits against unknown risks.

Granulokine may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Concurrent use with chemotherapy agents that cause profound myelosuppression without appropriate timing. - Combination with other colony‑stimulating factors (e.g., sargramostim) unless specifically directed.

Use with caution: - Antimicrobial agents such as penicillins that may mask infection signs. - Corticosteroids, which can alter neutrophil dynamics. - Immunosuppressive drugs that could modify the expected rise in neutrophil counts.